IO Biotech, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a IOBT research report →
Companywww.iobiotech.com
IO Biotech, Inc. , a clinical-stage biopharmaceutical company, develops immune-modulating cancer therapies based on the T-win technology platform. The company's lead product candidate, IO102-IO103, which is designed to target immunosuppressive proteins, such as Indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand (PD-L1) that is in phase 2 clinical trial to treat melanoma, as well as in phase 1 clinical trial to treat lung, head and neck, bladder, and melanoma cancer.
- CEO
- Mai-Britt Zocca
- IPO
- 2021
- Employees
- 80
- HQ
- Copenhagen, DK
Price Chart
Valuation
- Market Cap
- $885.69K
- P/E
- -0.01
- P/S
- 0.00
- P/B
- 0.90
- EV/EBITDA
- 0.32
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -465.36%
- ROIC
- -405.95%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-95,491,000 · -10.93%
- EPS
- $-1.45 · 26.77%
- Op Income
- $-95,177,000
- FCF YoY
- -14.34%
Performance & Tape
- 52W High
- $2.79
- 52W Low
- $0.01
- 50D MA
- $0.27
- 200D MA
- $0.95
- Beta
- 0.89
- Avg Volume
- 19.98M
Get TickerSpark's AI analysis on IOBT
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 5, 25 | Smith David V | other | 35,144 |
| Jun 5, 25 | Hunter Heidi | other | 35,144 |
| Jun 5, 25 | Hirth Peter | other | 35,144 |
| Jun 5, 25 | Glaub Kathleen Sereda | other | 35,144 |
| Jun 5, 25 | Elling Christian E | other | 35,144 |
| Jun 5, 25 | Collins Helen Louise | other | 35,144 |
| May 30, 25 | Hunter Heidi | buy | 15,000 |
| Apr 2, 25 | Zocca Mai-Britt | other | 580,000 |
| Apr 2, 25 | Sullivan Amy | other | 215,000 |
| Apr 2, 25 | Smith Devin Whittemore | other | 140,000 |
Our IOBT Coverage
We haven't published any research on IOBT yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate IOBT Report →